Characteristics of nine patients who were discontinued from YK preparations due to hypokalaemia
| Case | YK preparations | YK preparations dose (g/day) | Dosing period until hypokalaemia (days) | Minimum value of serum potassium (mEq/L) (reduction) | Baseline albumin (g/dL) | Symptoms | Co-medication | Number of risk factors |
| 1 | YK* | 7.5* | 205 | 1.9 (−2.5) | 4.1 | Oedema | Hydrochlorothiazide* | 3 |
| 2 | YK* | 7.5* | 554 | 2.0 (−3.0) | 4.1 | Rhabdomyolysis | – | 2 |
| 3 | YK* | 7.5* | 24 | 2.8 (−2.0) | 2.5* | – | – | 3 |
| 4 | YK* | 5.0 | 160 | 2.8 (−1.4) | – | – | – | 1 |
| 5 | YK* | 7.5* | 8 | 2.9 (−1.7) | 2.1* | – | Rikkunshito†* | 4 |
| 6 | YKCH | 7.5* | 161 | 2.9 (−1.1) | 3.7* | – | – | 2 |
| 7 | YK* | 5.0 | 237 | 3.3 (−0.6) | – | Oedema, hypertension | – | 1 |
| 8 | YK* | 5.0 | 26 | 3.3 (−0.5) | 2.6* | – | – | 2 |
| 9 | YKCH | 7.5* | 26 | 3.5 (−2.5) | 3.4* | – | – | 2 |
*Risk factors for hypokalaemia are: YK, LPIDs, hypoalbuminaemia, full dose.
†Other Kampo-medicine including glycyrrhiza.
LPIDs, lower potassium-inducing drugs; YK, Yokukansan; YKCH, Yokukansan-ka-chimpihange.